查詢結果分析
相關文獻
- 腫瘤標記CA19-9之文獻回顧
- Carbohydrate antigen (CA 19-9):A valuable tumor marker of pancreatic cancer
- 血清腫瘤標記的篩檢、判讀與應用
- 癌症研究新鋒叢談(6)--以致癌基因產物作為腫瘤標記的潛力
- 前列腺癌腫瘤標記(PSA)最新應用及發展
- 腫瘤標記鱗狀上皮癌抗原
- Tissue Polypeptide Antigen and Carcinoembryonic Antigen as Tumor Markers in Lung Cancer
- 以安寧療護理念照顧一位胰臟癌末期病患之護理經驗
- An Overview of the Detection and Screening of Oral Cancer and Precancer
- 胰臟胰管內乳頭狀黏液性癌
頁籤選單縮合
題 名 | 腫瘤標記CA19-9之文獻回顧=A Review of Tumor Marker--CA19-9 |
---|---|
作 者 | 楊彬彬; 楊旻達; 王鐘貴; 李龍雄; 王朝欣; | 書刊名 | 內科學誌 |
卷 期 | 9:2 1998.06[民87.06] |
頁 次 | 頁63-69 |
分類號 | 415.138 |
關鍵詞 | 腫瘤標記; 胰臟癌; Tumor market; CA19-9; Carbohydrate antigen 19-9; Pancreatic carcinoma; |
語 文 | 中文(Chinese) |
中文摘要 | 癌症為第一大致死病因,目前癌症病患占總人口10%,在60歲至79歲老人當中, 男性每3人,女性每4人中即有1人得到癌症。目前平均壽命增加,人口高齡化的狀況下, 癌症的早日診斷及治療將是極重要的課題。 近幾年,因為單株抗體技術的運用,已可檢測出針對特殊類型腫瘤的特異腫瘤標記,為 臨床上用來輔助診斷及評估癌症的利器之一。CEA、AFP、HCG、CA19-9、CA125、CA15- 3、PSA等,在癌症之臨床監測上皆受到廣泛應用。其中CA19-9是一種與胰臟癌及腸胃道 腫瘤有強烈相關的腫瘤標記。 若以血清CA19-9濃度37U/ml為門檻值(cut off value)時,對胰臟癌的敏感度及特異性分 別為89.2%及85.7%。對其他腸胃道腫瘤、良性胰臟疾病、非腸胃道腫瘤及不明原因轉移癌 也分別有診斷價值。並且更可監測治療效果並早期發現癌症復發。 此外,亦可應用免疫組織化學法,鑑定腫瘤組織上CA19-6的分佈及特徵,以作為診斷 及預後的參考。 |
英文摘要 | Cancer is the first leading cause of death in Taiwan. The cancer incidence and death account about 10 percent popution. For individuals between ages 60 and 79 years, 1 in 3 men and 1 in 4 women will develop cancer. The life expectancy and senior population are so increasing in the future that early diagnosis and treatment of cancer is important. The detection for the abnormally cellular products that are elaborated by malignancies, because of the application of the monoclonal antibody, which became very useful in clinical diagnosis for cancer in the recent years. CEA, AFP, HCG, CA19-9, A125, CA15-3, PSA, et al, are useful for survey of malignancies. CA19-9 is the most accurate marker for monitoring pancreatic carcinoma and is also associated with gastrointestinal tract carcinoma. If we use 37U/ml as cut off value of serum level of CA19-9, the sensitivity and specificity for pancreatic cancer is 89-.2% and 85.7%. It is also useful in diagnosis for the other gastrointestinal tract carcinomas, benign pancreatic diseases, non-gastrointestinal tract carcinomas and unknown metastatic adenocarcinoma. CA19-9 can be used for monitoring the treatment efficacy and early recurrence. Besides, we can use the immunohistochemical localization of CA19-9 in malignant tissues for the biologic analysis, diagnosis and prognostic survey. |
本系統中英文摘要資訊取自各篇刊載內容。